Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FCZB9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,977
Award facts
- Contract value 100% obligated
- $28,977.45 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $28,977.45 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for NUCALA 100 mg/mL auto-injector units. The delivery order was issued on December 15, 2025, with an ultimate completion date of December 16, 2025, and carries no set-aside designation. This award represents a competitive procurement action under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a single-award contract valued at $500 million with a completion date extending to December 31, 2036. The PPV-G GEN V program is part of a broader $30.3 billion acquisition strategy designed to establish regional prime vendor contractors that supply comprehensive pharmaceutical products and medical consumables to military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance capability across the DLA's pharmaceutical supply chain, with recent delivery orders spanning a diverse product portfolio including specialty biologics, oncology treatments, vaccines, and emergency medications. As the sole awardee on this delivery order with no identified subcontractors, the company will directly supply the NUCALA product to support Department of Defense medical operations. The firm's established track record fulfilling high-value pharmaceutical delivery orders and its classification as a woman-owned small business position it as a critical supplier within the federal military medical system's pharmaceutical distribution network.
Quick answers
Who was awarded contract SPE2DR26FCZB9?
SPE2DR26FCZB9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 15, 2025.
How much is contract SPE2DR26FCZB9 worth?
The government has obligated $28,977 on SPE2DR26FCZB9.
Is contract SPE2DR26FCZB9 an order under another contract?
Yes. SPE2DR26FCZB9 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZB9 competed?
The extent of competition for SPE2DR26FCZB9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award